Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02993471 · ClinicalTrials.gov registry record · Phase 1
A Study of Ixekizumab in Participants With Plaque Psoriasis
A Phase 1 study, sponsored by Eli Lilly and Company.
- Completed
- Registry status
- Phase 1
- Development phase
- 28
- Enrollment target
NCT02993471 is a Phase 1 study that has completed, run by Eli Lilly and Company. The registered enrollment target is 28 participants.
The verdict
NCT02993471, a Phase 1 study, has completed, sponsored by Eli Lilly and Company.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 28 participants
- Enrollment target
Study Summary
This study is known as a "drug interaction study." The purpose is to learn about how ixekizumab may affect the blood levels of a mixture of commonly used drugs (caffeine, omeprazole, warfarin, dextromethorphan, and midazolam) that are metabolized by cytochrome P450. Each participant will complete two study periods. Participants will take the mixture of commonly used drugs (plus vitamin K) by mouth on 3 occasions (prior to treatment with ixekizumab and after 1 and 12 weeks of treatment with ixekizumab). The study will last about 17 weeks, including follow-up. Screening must be completed prior to study start.
Interventions
- DRUG Ixekizumab
- DRUG Drug Cocktail
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 28 participants |
| Start Date | 2016-12-22 |
| Est. Completion | 2017-11-21 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02993471
The ClinicalTrials.gov registry entry for NCT02993471 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 28 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Eli Lilly and Company, which has 1,341 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Ixekizumab is the first listed.
NCT02993471 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02993471 about?
NCT02993471 is a clinical study titled "A Study of Ixekizumab in Participants With Plaque Psoriasis". This study is known as a "drug interaction study." The purpose is to learn about how ixekizumab may affect the blood levels of a mixture of commonly used drugs (caffeine, omeprazole, warfarin, dextromethorphan, and midazolam) that are metabolized by cytochrome P450. Each participant will complete tw...
What is the current status of trial NCT02993471?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 28 participants. The study started on 2016-12-22. Estimated completion is 2017-11-21.
What interventions are being tested in trial NCT02993471?
The interventions under investigation include: Ixekizumab (DRUG), Drug Cocktail (DRUG).
Who is sponsoring clinical trial NCT02993471?
This trial is sponsored by Eli Lilly and Company, which has 1,341 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.